Artivion, Inc. $AORT Holdings Trimmed by Intech Investment Management LLC

Intech Investment Management LLC cut its holdings in Artivion, Inc. (NYSE:AORT) by 17.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,302 shares of the company’s stock after selling 5,047 shares during the quarter. Intech Investment Management LLC owned about 0.06% of Artivion worth $756,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of AORT. James Investment Research Inc. acquired a new position in shares of Artivion in the 2nd quarter worth approximately $210,000. Atria Investments Inc acquired a new position in Artivion in the second quarter worth approximately $244,000. Los Angeles Capital Management LLC bought a new position in shares of Artivion in the second quarter valued at $248,000. EntryPoint Capital LLC acquired a new stake in shares of Artivion during the 1st quarter valued at $284,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in shares of Artivion by 9.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,867 shares of the company’s stock valued at $307,000 after acquiring an additional 838 shares during the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Artivion news, SVP Marshall S. Stanton sold 47,376 shares of Artivion stock in a transaction on Friday, November 21st. The shares were sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the completion of the sale, the senior vice president owned 44,753 shares of the company’s stock, valued at $2,015,675.12. This trade represents a 51.42% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Hoff sold 4,200 shares of the company’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $45.10, for a total transaction of $189,420.00. Following the completion of the transaction, the director directly owned 27,189 shares in the company, valued at $1,226,223.90. This trade represents a 13.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 191,703 shares of company stock worth $8,669,234. Insiders own 7.60% of the company’s stock.

Artivion Trading Down 0.7%

NYSE:AORT opened at $46.51 on Thursday. The stock has a market cap of $2.20 billion, a PE ratio of -110.74 and a beta of 1.65. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.04. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The stock’s 50-day moving average is $43.37 and its two-hundred day moving average is $37.35.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.02. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business had revenue of $113.39 million during the quarter, compared to analyst estimates of $110.71 million. Artivion’s revenue for the quarter was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on AORT shares. Canaccord Genuity Group boosted their target price on Artivion from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Wall Street Zen raised Artivion from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Oppenheimer reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Citigroup reiterated an “outperform” rating on shares of Artivion in a report on Friday, October 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Artivion currently has a consensus rating of “Moderate Buy” and an average target price of $49.11.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.